NCT04923542: Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Endocrine (Hormone Therapy, Radiation therapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have 15 brain metastases or less and be eligible for stereotactic radiation
Exclusions: Patients with brain metastases greater than or equal to 4 cm; Patients with leptomeningeal disease; Patients with prior receipt of whole brain radiation therapy; Patients with prior receipt of abemaciclib for treatment of metastatic disease

Comments are closed.

Up ↑